Tyrosine Kinase Inhibitor
Tuspetinib for Acute Myeloid Leukemia
This trial is testing a new drug, HM43239, for patients with relapsed or refractory acute myeloid leukemia (AML). The goal is to find the safe dose range and to see how well the drug works.
Anti-tumor antibiotic
BH-30236 for Acute Myeloid Leukemia and Myelodysplastic Syndrome
"This trial is studying a new drug for people with relapsed or refractory acute myelogenous leukemia or higher-risk myelodysplastic syndrome. The study has two phases: Phase 1
Popular Filters
Trials for Acute Myeloid Leukemia Patients
CAR T-cell Therapy
JNJ-75276617 Combination Therapy for Acute Myeloid Leukemia
This trial tests JNJ-75276617, an oral drug that blocks a key protein interaction in leukemia cells. It targets adults with AML who have specific genetic changes making their disease hard to treat. The drug aims to stop cancer cells from growing and spreading.
Chemotherapy
DSP-5336 for Leukemia
This trial is testing a new drug called DSP 5336 to help treat adults with certain types of blood cancer that have come back or didn't respond to previous treatments. The study will first find the best amount to give and then check how safe and helpful it is.
Chemotherapy
CC-91633 for Leukemia
This trial tests a new drug, CC-91633, for patients with certain blood cancers that haven't responded to other treatments. Researchers will find the safest dose by increasing it over time and checking for side effects and effectiveness.
Behavioural Intervention
High-Fiber/Low-Fat Diet for C. diff Infection Prevention in Cancer Patients
This trial is testing if a diet with more fiber and less fat can help prevent C. difficile infections from coming back in cancer patients. The idea is that this diet might improve gut health by supporting good bacteria and reducing bad bacteria.
Trials for Acute Promyelocytic Leukemia Patients
CAR T-cell Therapy
JNJ-75276617 Combination Therapy for Acute Myeloid Leukemia
This trial tests JNJ-75276617, an oral drug that blocks a key protein interaction in leukemia cells. It targets adults with AML who have specific genetic changes making their disease hard to treat. The drug aims to stop cancer cells from growing and spreading.
Chemotherapy
DSP-5336 for Leukemia
This trial is testing a new drug called DSP 5336 to help treat adults with certain types of blood cancer that have come back or didn't respond to previous treatments. The study will first find the best amount to give and then check how safe and helpful it is.
Chemotherapy
CC-91633 for Leukemia
This trial tests a new drug, CC-91633, for patients with certain blood cancers that haven't responded to other treatments. Researchers will find the safest dose by increasing it over time and checking for side effects and effectiveness.
Behavioural Intervention
High-Fiber/Low-Fat Diet for C. diff Infection Prevention in Cancer Patients
This trial is testing if a diet with more fiber and less fat can help prevent C. difficile infections from coming back in cancer patients. The idea is that this diet might improve gut health by supporting good bacteria and reducing bad bacteria.
Trials for CD19 Positive Patients
CAR T-cell Therapy
CD19 CAR-T Cells for Leukemia and Lymphoma
This trial is testing a new treatment for leukemia and lymphoma that uses a combination of two types of blood cells, T cells and antibodies. The hope is that this will be a more effective treatment with fewer side effects than current treatments.
CAR T-cell Therapy
CAR T-Cell Therapy for Leukemia and Lymphoma
This trial is testing a new cancer treatment combining two existing methods: T cells and antibodies. Researchers hope that the combination will be stronger than either method alone in fighting the cancer.
Monoclonal Antibodies
Rituximab + Bendamustine/Ibrutinib for Chronic Lymphocytic Leukemia
This trial is testing rituximab with bendamustine hydrochloride or ibrutinib compared to ibrutinib alone to see how well they work in treating patients with previously untreated chronic lymphocytic leukemia.
Immunomodulatory Agent
Triple Therapy for CLL/SLL
This trial is studying the side effects and best dose of lenalidomide when given with ibrutinib and rituximab to treat patients with CLL or SLL that has come back, is refractory, has spread, or cannot be removed by surgery.
Phase 3 Trials
IDH1 Inhibitor
Ivosidenib + Azacitidine for Acute Myeloid Leukemia
This trial is testing a new oral drug, ivosidenib, combined with an injectable drug, azacitidine. It targets adults with a specific type of untreated leukemia who can't undergo intensive treatments. Ivosidenib blocks a faulty enzyme in cancer cells, and azacitidine stops these cells from growing.
Radioimmunotherapy
Iomab-B + HCT for Acute Myeloid Leukemia
This trial is testing a new treatment for AML patients who have relapsed or are unresponsive to other treatments. The new treatment consists of a reduced intensity conditioning regimen in conjunction with Iomab-B and allogeneic hematopoietic stem cell transplant.
Chemotherapy
New Cancer Treatment for Non-Hodgkin's Lymphoma
This trial is testing a new cancer treatment for children with B-cell NHL. The new treatment is based on the successful LMB-96 regimen. The trial features prospective biologic and late effect studies.
Trials With No Placebo
CAR T-cell Therapy
JNJ-75276617 Combination Therapy for Acute Myeloid Leukemia
This trial tests JNJ-75276617, an oral drug that blocks a key protein interaction in leukemia cells. It targets adults with AML who have specific genetic changes making their disease hard to treat. The drug aims to stop cancer cells from growing and spreading.
Chemotherapy
DSP-5336 for Leukemia
This trial is testing a new drug called DSP 5336 to help treat adults with certain types of blood cancer that have come back or didn't respond to previous treatments. The study will first find the best amount to give and then check how safe and helpful it is.
Chemotherapy
CC-91633 for Leukemia
This trial tests a new drug, CC-91633, for patients with certain blood cancers that haven't responded to other treatments. Researchers will find the safest dose by increasing it over time and checking for side effects and effectiveness.
Behavioural Intervention
High-Fiber/Low-Fat Diet for C. diff Infection Prevention in Cancer Patients
This trial is testing if a diet with more fiber and less fat can help prevent C. difficile infections from coming back in cancer patients. The idea is that this diet might improve gut health by supporting good bacteria and reducing bad bacteria.
View More Related Trials
Frequently Asked Questions
Introduction to acute myelogenous leukemia
What are the top hospitals conducting acute myelogenous leukemia research?
In the battle against acute myelogenous leukemia (AML), several leading hospitals are at the forefront of groundbreaking clinical trials. At Loyola University Medical Center in Maywood, Illinois, researchers are actively engaged in 10 AML trials, building on a strong foundation of 28 completed studies since their first recorded trial in 2000. Similarly dedicated to advancing AML treatment is M D Anderson Cancer Center in Houston, Texas, which currently has 10 ongoing trials and an impressive track record of 93 past investigations dating back to 1999. The University of Chicago Comprehensive Cancer Center also plays a pivotal role with its own set of 10 active AML trials and a total count of 25 previous studies conducted since they initiated their first trial in this field in 2003.
Meanwhile, Memorial Sloan Kettering Cancer Center located in New york City contributes significantly to the progress made against AML with nine ongoing clinical trials and an outstanding tally of 78 previously conducted investigations since recording their inaugural trial for this condition back in the year2002. Notably thriving as well is Roswell Park Cancer Institute situatedin Buffalo where there are nine current acute myelogenous leukemia tests going strong while standing out among all these renowned facilities by having played a part incompleting an astounding numberof107 prior researches starting fromback as earlyas1997!
These top-tier hospitals across different locations embody hope for those affected by AML as they tirelessly work towards finding more effective treatments and ultimately a cure for this aggressive blood cancer. Their collective efforts highlight significant strides being taken toward improving patient outcomes while underscoring the importance of continued research and innovation within the medical community
Which are the best cities for acute myelogenous leukemia clinical trials?
When it comes to acute myelogenous leukemia (AML) clinical trials, several cities emerge as top contenders in advancing research and treatment options. Chicago, Illinois leads the pack with 53 active trials focusing on promising therapies such as Dasatinib, AG-120, and Lenalidomide. Following closely behind is Boston, Massachusetts with 47 ongoing studies investigating treatments like AG-120, CC-90009, and other interventions. Houston, Texas also shows promise with 45 active trials exploring Dasatinib, CC-486, CC-90009 among others for AML patients. These cities provide individuals diagnosed with AML access to cutting-edge clinical trials that hold potential for improved outcomes and novel therapeutic approaches.
Which are the top treatments for acute myelogenous leukemia being explored in clinical trials?
Exciting advancements are taking place in clinical trials exploring treatments for acute myelogenous leukemia. Among the top contenders is a pharmacological study, which currently has five active trials dedicated to this form of leukemia and an impressive 35 all-time trials since its initial listing in 2006. Another promising option is dasatinib, with three ongoing trials and a total of 12 historical clinical studies focused on acute myelogenous leukemia since it was first listed in 2009. Additionally, rituximab is showing potential with three active trials and 11 previous studies specifically targeting this type of leukemia since its introduction in 2013. Notably, cyclophosphamide also holds promise as a treatment for acute myelogenous leukemia, boasting involvement in three current trials and an extensive portfolio of 76 historical studies dating back to its initial listing in 2000. These advancements provide hope for patients battling this challenging disease.
What are the most recent clinical trials for acute myelogenous leukemia?
Recent clinical trials offer promising prospects for individuals with acute myelogenous leukemia, a challenging form of blood cancer. Regimen A, which combines TBI, Thiotepa, and Cyclophosphamide, has entered Phase 2 trials and demonstrates potential as an effective treatment option. Additionally, Flotetuzumab has shown promise in Phase 1 trials as a targeted therapy for acute myelogenous leukemia. Another experimental drug under investigation is JNJ-75276617, also in its Phase 1 trial stage. Lastly, DSP-5336 and CC-95251 are other compounds being studied at varying stages to explore their efficacy against this aggressive disease. With these advancements on the horizon, there is hope for improved outcomes and better quality of life for those battling acute myelogenous leukemia.
What acute myelogenous leukemia clinical trials were recently completed?
Recent clinical trials for acute myelogenous leukemia have made significant strides in advancing treatment options. In June 2021, AbbVie completed a trial investigating Lemzoparlimab's potential to combat this aggressive form of leukemia. Likewise, Pfizer concluded their Azacitidine study in May 2021. Bhavana Bhatnagar successfully wrapped up the Dubermatinib trial in November 2020, while Rutgers, The State University of New jersey completed their Salsalate investigation in October 2020. These groundbreaking trials underline the ongoing efforts to improve outcomes and provide hope for patients battling acute myelogenous leukemia.